TIDMDDDD
RNS Number : 4855Q
4d Pharma PLC
01 March 2021
4D Pharma Appoints Paul Maier to the Board as Non-Executive
Director
Leeds, UK, March 1, 2021 , - 4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announces the appointment of Paul Maier as
Non-Executive Director of the Board. Mr Maier will also be a member
of 4D's Audit and Risk Committee and will serve as the Company's
"audit committee financial expert" under SEC and Nasdaq rules.
"With over 25 years of extensive senior operational,
international and financial management experience in the
pharmaceutical and biotechnology industry, Paul will be able to
provide 4D pharma with invaluable insights as we continue to
execute across our business both clinically and operationally,"
said Duncan Peyton, Chief Executive Officer of 4D pharma. "Paul's
strong track record will support our Board with additional
perspective and expertise."
"I am excited to join 4D pharma's Board and support its goals to
establish a larger global presence while working to bring its
differentiated approach and pipeline of Live Biotherapeutics to
patients in need," said Paul Maier, Non-Executive Director of 4D
pharma. "I look forward to working with 4D and offering my
experiences in transactional and operational strategy as the
company continues to grow, catalyzed by 4D's upcoming NASDAQ
listing."
Mr. Maier has over 25 years of investor and public relations,
operational, regulatory, and finance expertise in the healthcare
industry. Mr. Maier was previously the Chief Financial Officer of
Sequenom Inc., where he was responsible for raising over $360
million in equity and debt financings, expanding institutional sell
side research analyst coverage, as well as overseeing and
establishing internal financial infrastructure. Previously, he was
Senior Vice President and Chief Financial Officer of Ligand
Pharmaceuticals (NASDAQ: LGND) where he helped build Ligand from a
venture stage company to a commercial, integrated biopharmaceutical
organization, raising over $1 billion in equity and debt financings
including a successful IPO, and helped negotiate multiple R&D
and commercial partnerships and transactions. He has also acted as
an independent financial consultant to life sciences companies. Mr.
Maier is currently a Board member of Eton Pharmaceuticals, Inc,
Biological Dynamics and International Stem Cell Corporation (OTCQB:
ISCO). He holds an MBA from Harvard University and a BS in Business
Logistics from the Pennsylvania State University.
Additional Disclosures Required under the AIM Rules for
Companies
In accordance with Schedule 2(g) of the AIM Rules, Paul Victor
Maier (aged 73) currently holds the following directorships:
Eton Pharmaceuticals, Inc
Biological Dynamics, Inc
International Stem Cell Corp.
Previous directorships held in the past five years:
Ritter Pharmaceuticals, Inc (Mar 2015 - May 2020)
Apricus Biosciences, Inc (May 2012 - Jan 2019)
Mabvax, Inc (June 2014 - July 2018)
Paul Maier does not currently hold any ordinary shares in the
Company.
Save as set out above there are no further disclosures pursuant
to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies in respect of the appointment of Paul Maier.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of
MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372),
and Blautix(R) in Irritable Bowel Syndrome (IBS) (NCT03721107)
which has completed a successful Phase II trial. Preclinical-stage
programs include candidates for CNS disease such as Parkinson's
disease and other neurodegenerative conditions. The Company has a
research collaboration with MSD, a tradename of Merck & Co.,
Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to www.4dpharmaplc.com .
Contact Information:
4D pharma
Investor Relations: ir@4dpharmaplc.com
Stern Investor Relations, Inc.
Julie Seidel
+1-212-362-1200
Julie.seidel@sternir.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Philip Davies / Iqra Amin / James Fischer (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
Forward-Looking Statements
This press release contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding timing of the clinical trial are forward-looking
statements within the meaning of Section 27A of the United States
Securities Act of 1933, as amended (the "Securities Act"), and
Section 21E of the United States Securities Exchange Act of 1934,
as amended (the "Exchange Act"). Forward-looking statements are
often identified by the words "believe," "expect, " "anticipate,"
"plan," "intend," "foresee," "should," "would," "could," "may,"
"estimate," "outlook" and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company's business, including the risks of delays in the
commencement of the clinical trial and those additional risks and
uncertainties described the documents filed by the Company with the
US Securities and Exchange Commission ("SEC"), should be carefully
considered. The Company wishes to caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update or revise any of its forward-looking statements after the
date they are made, whether as a result of new information, future
events or otherwise, except to the extent required by law.
Additional Information about the Merger and Where to Find it
This press release is being made in respect of a proposed
business combination involving 4D and Longevity. Following the
announcement of the proposed business combination, 4D filed a
registration statement on Form F-4 (the "Registration Statement")
with the SEC which was declared effective on February 25, 2021.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy or subscribe for any securities or
a solicitation of any vote or approval nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. The Registration Statement includes a prospectus with
respect to 4D's ordinary shares and ADSs to be issued in the
proposed transaction and a proxy statement of Longevity in
connection with the merger. The proxy statement/prospectus has been
mailed to the Longevity shareholders on or about February 26, 2021.
4D and Longevity also plan to file other documents with the SEC
regarding the proposed transaction.
This press release is not a substitute for any prospectus, proxy
statement or any other document that 4D or Longevity may file with
the SEC in connection with the proposed transaction. Investors and
security holders are urged to read the Registration Statement and,
when they become available, any other relevant documents that will
be filed with the SEC carefully and in their entirety because they
will contain important information about the proposed
transaction.
You may obtain copies of all documents filed with the SEC
regarding this transaction, free of charge, at the SEC's website
(www.sec.gov). In addition, investors and security holders will be
able to obtain free copies of the Registration Statement and other
documents filed with the SEC without charge, at the SEC's website
(www.sec.gov) or by calling +1-800-SEC-0330.
Participants in the Solicitation
Longevity and its directors and executive officers and other
persons may be deemed to be participants in the solicitation of
proxies from Longevity's shareholders with respect to the proposed
transaction. Information regarding Longevity's directors and
executive officers is available in its annual report on Form 10-K
for the fiscal year ended February 29, 2020, filed with the SEC on
April 30, 2020. Additional information regarding the participants
in the proxy solicitation relating to the proposed transaction and
a description of their direct and indirect interests is contained
in the Registration Statement.
4D and its directors and executive officers may also be deemed
to be participants in the solicitation of proxies from the
shareholders of Longevity in connection with the proposed
transaction. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
transaction is included in the Registration Statement.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASEUSWMEFSEDE
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024